The company posted adjusted earnings of $2.77 per share on revenue of $21.9 billion, exceeding consensus estimates of $2.59 ...

Barclays lowered the firm’s price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following ...

Raymond James raised the firm’s price target on Johnson & Johnson to $164 from $162 and keeps an Outperform rating on the shares. The firm ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.